Optina (Microvascular Complications of Diabetes)- Market Size, Strategies & Forecast to 2022

1
Optina (Microvascular Complications of Diabetes)
Forecast and Market Analysis to
2022byGlobalData

• Explore all reports for Diabetes Therapeutics
  market
• _at_
• http//www.rnrmarketresearch.com/reports/life-scie
  nces/pharmaceuticals/therapeutics/diabetes-therape
  utics .

2
Optina (Microvascular Complications of Diabetes)
- Forecast and Market Analysis to 2022

• The entire market for Microvascular Complications
  of Diabetes (MCD) diabetic nephropathy,
  retinopathy, and neuropathy is facing an
  extremely high level of unmet need across the 7MM
  (US, 5EU and Japan). Despite its enormous
  potential, the MCD market is facing the major
  global barrier in the sparsely populated
  pipeline. The diabetic retinopathy segment of the
  market has recently seen rapid uptake of novel
  anti-VEGF therapies and is experiencing a strong
  growth. On the other hand, the diabetic
  neuropathy and nephropathy segments face the
  barrier in and increasing number of generic
  competitors.
• Optina (danazol) has been developed by Ampio
  Pharmaceuticals and is currently in Phase III
  trials for the treatment of diabetic retinopathy
  and DME. Effective non-surgical drug treatment of
  diabetic retinopathy is a high unmet need and
  Optina is the only drug in late-phase development
  addressing this need.
• Request sample copy of this report _at_
  http//www.rnrmarketresearch.com/contacts/request-
  sample?rname147162 .

3
Optina (Microvascular Complications of Diabetes)
- Forecast and Market Analysis to 2022

• Scope
• Overview of MCD, including epidemiology,
  etiology, symptoms, diagnosis, pathology and
  treatment guidelines as well as an overview on
  the competitive landscape.
• Detailed information on Optina including product
  description, safety and efficacy profiles as well
  as a SWOT analysis.
• Sales forecast for Optina for the top seven
  countries from 2012 to 2022.
• Sales information covered for the US, France,
  Germany, Italy, Spain, the UK and Japan.
• Reasons to buy
• Understand and capitalize by identifying products
  that are most likely to ensure a robust return.
• Complete report available _at_ http//www.rnrmarketre
  search.com/optina-microvascular-complications-of-d
  iabetes-forecast-and-market-analysis-to-2022-marke
  t-report.html .

4
Optina (Microvascular Complications of Diabetes)
- Forecast and Market Analysis to 2022

• Stay ahead of the competition by understanding
  the changing competitive landscape for MCD
• Effectively plan your MA and partnership
  strategies by identifying drugs with the most
  promising sales potential
• Make more informed business decisions from
  insightful and in-depth analysis of Optina
  performance
• Obtain sales forecast for Optina from 2012-2022
  in top seven countries (the US, France, Germany,
  Italy, Spain, the UK and Japan)
• Table Of Contents
• 1 Table of Contents1 Table of Contents 61.1
  List of Tables 91.2 List of Figures 9
• Request sample copy of this report _at_
  http//www.rnrmarketresearch.com/contacts/request-
  sample?rname147162 .

5
Optina (Microvascular Complications of Diabetes)
- Forecast and Market Analysis to 2022

• 2 Introduction 102.1 Catalyst 102.2 Related
  Reports 11
• 3 Disease Overview 133.1 Etiology and
  Pathophysiology 153.1.1 Diabetic Nephropathy
  153.1.2 Diabetic Retinopathy 173.1.3 Diabetic
  Neuropathy 183.2 Prognosis 193.3 Quality of
  Life 203.4 Symptoms 21
• 4 Disease Management 224.1 Treatment Overview
  22
• Complete report available _at_ http//www.rnrmarketre
  search.com/optina-microvascular-complications-of-d
  iabetes-forecast-and-market-analysis-to-2022-marke
  t-report.html .

6
Optina (Microvascular Complications of Diabetes)
- Forecast and Market Analysis to 2022

• 4.1.1 Diagnosis and Referrals 224.1.2 Screening
  244.1.3 Treatment Guidelines 25
• 5 Competitive Assessment 335.1 Overview 335.2
  Strategic Competitor Assessment 34
• 6 Opportunity and Unmet Need 386.1 Overview
  386.2 Unmet Needs 396.2.1 Unified Treatment for
  the Microvascular Complications of Diabetes
  396.2.2 Optimization of Personalized Therapy in
  the Microvascular Complications of Diabetes
  396.2.3 Treatment for Diabetic Nephropathy that
  Would Prevent ESRD 41
• Request sample copy of this report _at_
  http//www.rnrmarketresearch.com/contacts/request-
  sample?rname147162 .

7
Optina (Microvascular Complications of Diabetes)
- Forecast and Market Analysis to 2022

• 6.2.4 Cardio- and Renoprotective Therapy for
  Diabetic Nephropathy 426.2.5 Efficient Therapy
  for Retinopathy 436.2.6 Convenient
  Administration in Diabetic Retinopathy Treatment
  436.2.7 Treatment for Diabetic Neuropathy 446.3
  Unmet Needs Gap Analysis 456.4 Opportunity
  Therapy for the Underlying Cause of the
  Microvascular Complications of Diabetes 476.5
  Opportunity Patient-Tailored Therapy for the
  Microvascular Complications of Diabetes 476.6
  Opportunity Efficacious Therapy for Diabetic
  Nephropathy 486.7 Opportunity Topical Treatment
  for Diabetic Retinopathy 486.8 Opportunity
  Treatment for Diabetic Neuropathy 49
• Complete report available _at_ http//www.rnrmarketre
  search.com/optina-microvascular-complications-of-d
  iabetes-forecast-and-market-analysis-to-2022-marke
  t-report.html .

8
Optina (Microvascular Complications of Diabetes)
- Forecast and Market Analysis to 2022

• 7 Pipeline Assessment 507.1 Overview 507.2
  Promising Drugs in Clinical Development 52
• 8 Optina (danazol) 548.1 Overview 548.2
  Efficacy 558.3 Safety 568.4 Dosing and
  Formulation 568.5 Potential Clinical Positioning
  578.6 Potential Commercial Positioning 578.7
  Pricing and Reimbursement 578.8 SWOT Analysis
  588.9 Forecast 58
• Request sample copy of this report _at_
  http//www.rnrmarketresearch.com/contacts/request-
  sample?rname147162 .

9
Optina (Microvascular Complications of Diabetes)
- Forecast and Market Analysis to 2022

• 9 Appendix 609.1 Bibliography 609.2
  Abbreviations 649.3 Methodology 669.4
  Forecasting Methodology 669.4.1 Diagnosed
  Patients 669.4.2 Percent Drug-Treated Patients
  679.4.3 General Pricing Assumptions 679.4.4
  Generic Erosion 689.4.5 Pricing of Pipeline
  Agents 68
• 9.5 Physicians and Specialists Included in this
  Study 699.6 About the Authors 71
• Complete report available _at_ http//www.rnrmarketre
  search.com/optina-microvascular-complications-of-d
  iabetes-forecast-and-market-analysis-to-2022-marke
  t-report.html .

10
Optina (Microvascular Complications of Diabetes)
- Forecast and Market Analysis to 2022

• 9.6.1 Analyst II - CVMD 719.6.2 Therapy Director
  - CVMD and Infectious Disease 719.6.3 Global
  Head of Healthcare 729.7 About Researcher 739.8
  Disclaimer 73
• Request sample copy of this report _at_
  http//www.rnrmarketresearch.com/contacts/request-
  sample?rname147162 .

11
Optina (Microvascular Complications of Diabetes)
- Forecast and Market Analysis to 2022

• For more details contact Mr. Priyank Tiwari
  sales_at_rnrmarketresearch.com / 18883915441

RnR Market Research RnRMarketResearch.com, an
online repository of market  research reports,
offers in-depth analysis of over 5000 market
segments. RnR  Market Research library has
syndicated reports by leading market research 
publishers across the globe.